Company Mission:
To become a world leader in the development of targeted, curative therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
Scientific Overview:
Aligos Therapeutics is discovering and developing new classes of compounds that interact directly with disease causing molecules. These approaches are targeting viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins. The company is also pursuing novel therapeutic agents aimed at activation of the immune system to resolve diseases that cause significant morbidity and mortality.
Location: United States, California, South San Francisco
Employees: 51-200
Founded date: 2018
Investors 3
Mentions in press and media 2
| Date | Title | Description | Source |
| 12.03.2024 | Aligos Therapeutics Reports Recent Business Progress and Fou... | SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A... | einpresswi... |
| 05.03.2024 | Aligos Therapeutics to Announce 4th Quarter 2023 Financial R... | - | globenewsw... |